This product is a mucus regulator, which mainly acts on the secretion of bronchial glands, increasing the secretion of low-viscosity salivary mucin and reducing the production of high-viscosity fucoxomucin, thereby reducing the viscosity of sputum and making it easier to cough up. It takes effect quickly after oral administration, and obvious therapeutic effects can be seen within 4 hours of taking it.

It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

It is an antihistamine that can relieve symptoms such as runny nose, nasal congestion, and sneezing.

Antipyretic and sedative effects

Sulfonylurea is an oral hypoglycemic diabetes treatment drug. It lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, it can restore the peak of first-phase insulin secretion in response to glucose and increase first-phase insulin secretion. The insulin secretion response induced or stimulated by glucose after a meal is significantly increased. In addition, it partially inhibits platelet adhesion and aggregation, reduces platelet activity markers (P-thromboglobulin, thromboxane B2), and produces fibrinolytic activity on the vascular endothelium (increases tPA activity), reducing the microthrombosis process.

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.